You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)上半年總產品收入超52億元 同比增長超過35%
格隆匯 08-07 17:35

格隆匯8月7日丨信達生物(01801.HK)公佈,於2025年上半年,公司共取得總產品收入超人民幣52億元,同比保持35%以上的強勁增長;其中2025年第二季度總產品收入超過人民幣27億元,同比增長超過30%。該季度的持續增長得益於腫瘤和綜合管線雙輪驅動共同發力:1)腫瘤治療領域的領導品牌和產品組合強大,主要產品保持優異增長,新產品收入貢獻持續提升;及2)綜合產品線潛力逐漸釋放,貢獻增長新驅動力:信必樂®(託萊西單抗注射液)和信必敏®(替妥尤單抗N01注射液)市場營銷和渠道準入工作順利推進,產品持續放量。於季度末,全球首個胰高血糖素╱胰高血糖素樣肽-1(GCG/GLP-1)雙受體激動藥物信爾美®(瑪仕度肽注射液)的減重適應症亦獲得中國國家藥品監督管理局批準上市,爲公司在綜合產品線領域的佈局再添一款重要品種。

公司致力可持續成長與全球創新兩大戰略,佈局了腫瘤與綜合產品線(心血管及代謝、自身免疫及眼科)的豐厚管線。截至目前,公司已取得16款產品獲批上市,2個品種在中國國家藥品監督管理局審評中,4個新藥分子進入3期或關鍵性臨牀研究,另外約15個新藥品種已進入臨牀研究。2025年是公司邁入雙輪驅動和全球創新發展新時期的重要一年,將朝着「成爲國際一流的生物製藥公司」的願景穩步邁進。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account